Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

With old-school technology, can Novavax win over COVID vaccine skeptics?

Since their debut just 18 months ago, three COVID-19 vaccines have saved an estimated 2.2 million American lives, changed the trajectory of a pandemic and inspired all manner of conspiracy theories.

Los Angeles Times

FDA authorizes first COVID booster for children ages 5 to 11

The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.

WEKU

FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT

The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children aged 5 to 11 probably by today, the New York Times reported, citing people familiar with the matter. The companies submitted an application to the FDA for authorization last month. They have cited data from…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Boeing’s Starliner spacecraft takes another shot at the International Space Station

In this edition of Horizons, learn about Boeing's Starliner capsule test, mRNA vaccine technology updates, and more from the world of innovation.

Inverse

Worried parents told kids' jabs are safe

The Department of Health is urging parents to take their children for Covid-19 shots ahead of the new school term this month.

Bangkok Post

Australia risks relying on Pfizer and Moderna for its COVID vaccines. 3 ways to break free

The rapid development and deployment of COVID vaccines has been one of the greatest achievements of the pandemic.

The Conversation

Gov won't say if Paxlovid is accessible

Officials won't say how many people have received antiviral pills, or if they're being equitably distributed

Salon

Read news from The Economist, FT, and more,
with one subscription

Only 7% of 5-11s in England have had Covid jab as parents hesitate

Six weeks after start of vaccine rollout, fraction of young children have had first dose as parents question usefulness

The Guardian - UK

We looked into the lobby group taking on rugby star turned would-be senator David Pocock. Here's what we found

Conservative lobby group Advance Australia has independent ACT Senate candidate David Pocock in its sights, with Facebook advertising data revealing that the group's offensive against the former rugby star is disproportionate to its campaigning against any other candidate.

ABC News

Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries

Several generic drugmakers will produce cheaper versions of Pfizer Inc's (NYSE:PFE) COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported citing the Clinton Health Access Initiative (CHAI). CHAI said it could not disclose the manufacturers' names who have agreed to the price ceiling because they are still in…

Benzinga

Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc (NASDAQ:MRNA) had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For…

Benzinga

Fourth Covid vaccine provides 'a substantial boost to immunity', according to new study

Several countries have now deployed fourth doses of the Covid-19 vaccine, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain

Daily Mirror

Biden administration and GOP clash over vaccine strategy

The administration wants to keep access as open as possible, but the GOP wants to reduce wastage.

Axios

COVID-19 Symptoms Rebound After Pfizer's COVID-19 Therapy, What Could Be The Reason?

Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's (NYSE: PFE) COVID-19 oral antiviral treatment Paxlovid.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

3 ways to get COVID pills, if you've just tested positive

Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.

Tribune News Service

Commentary: The US is doing too little to monitor Paxlovid use

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the COVID-19 oral-antiviral market.

Benzinga

Looking At Pfizer's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Independent UK

WHO calls on Pfizer to make its COVID pill more available

The head of the World Health Organization has called on Pfizer to make its COVID-19 treatment more widely available in poorer countries

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Covid vaccines are ‘safe for pregnant women and cut stillbirth risk’, study says

Unvaccinated pregnant women who catch Covid-19 are more likely to fall seriously ill

Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

The Independent UK

Pfizer to spend $11.6B on migraine treatment maker Biohaven

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

Daily Record

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

The Guardian - UK

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Wales Online

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

1 … 54 55 56 57

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.